Anticoagulant treatment for isolated distal deep vein thrombosis: a systematic review and meta-analysis

Matteo Guarascio,¹ Emanuele Valeriani,²,³ Laura Girardi,⁴ Matteo Candeloro,⁵ Arianna Pannunzio,² Ilaria Maria Palumbo,² Marcello Di Nisio⁶ and Walter Ageno^{4,7}

¹Internal Medicine Unit, Vito Fazzi Hospital, Lecce, Italy; ²Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy; ³Infectious Disease Department, Umberto I Hospital of Rome, Rome, Italy; ⁴Department of Medicine and Surgery, Research Center on Thromboembolic Diseases and Antithrombotic Therapies, University of Insubria, Varese, Italy; ⁵Department of Innovative Technologies in Medicine and Dentistry, "G. D'Annunzio" University, Chieti-Pescara, Italy; ⁶Department of Medicine and Aging Sciences, "G. D'Annunzio" University of Chieti-Pescara, Chieti, Italy and ⁷Department of Internal Medicine, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland

Correspondence: M. Guarascio guarasciomatteo@gmail.com

November 22, 2024. Accepted: May 9, 2025. May 22, 2025. Early view:

https://doi.org/10.3324/haematol.2024.286963

©2025 Ferrata Storti Foundation Published under a CC BY-NC license



SUPPLEMENTARY MATERIALS

Complete references list of studies included in the analysis

Ageno W, Bertù L, Bucherini E, Camporese G, Dentali F, Iotti M, Lessiani G, Parisi R, Prandoni P, Sartori M, Visonà A, Bigagli E, Palareti G. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: Randomised controlled trial. *BMJ* 2022; 379:e072623.

Ageno W, Mantovani L, Haas S, Kreutz R, Monje D, Schneider J, Bugge J-P, Gebel M, Turpie A. Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. *TH Open* Georg Thieme Verlag KG; 2019; 03: e85–93.

Asonitis K, Charvalos E, Lambert C, Hermans C. Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis. *J Thromb Thrombolysis* 2020; 50: 837–43.

Astermark J, Björgell O, Lindén E, Lethagen S, Nilsson P, Berntorp E. Low recurrence rate after deep calfvein thrombosis with 6 weeks of oral anticoagulation. *J Intern Med* 1998; 244: 79–82.

Barco S, Corti M, Trinchero A, Picchi C, Ambaglio C, Konstantinides S V, Dentali F, Barone M. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. *J Thromb Haemost* 2017; 15: 1436–42.

Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Incandela L, Dugall M, Mezzanotte L. Prevention of the extension of distal deep venous thrombosis. A randomized controlled trial with a 6-month follow-up. *Minerva Med* 1997; 88: 507–14.

Brateanu A, Patel K, Chagin K, Tunsupon P, Yampikulsakul P, Shah G V., Wangsiricharoen S, Amah L, Allen J, Shapiro A, Gupta N, Morgan L, Kumar R, Nielsen C, Rothberg MB. Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis. *Thromb Haemost* 2016; 115: 608–14.

Brewster AC, Jones AE, Johnson SA, Saunders JA, Witt DM. Outcomes of isolated distal thrombosis managed with serial compression ultrasonography. *Thromb Res* 2021; 208: 66–70.

Cox S, Moawad JA, Marshall LA, Petrinec D, McShannic J, Fink JA. Outpatient Surveillance Protocol of Isolated Calf Deep-Vein Thrombosis. *Journal for Vascular Ultrasound* 2014; 38: 76–9.

Day T, Tran H, Chunilal S, Bortz H, Esterman A. Isolated distal DVT in trauma: A study of the management of isolated distal deep vein thrombosis acquired as an inpatient in trauma patients. *Injury* 2022; 53: 2562–6.

Donadini MP, Dentali F, Pegoraro S, Pomero F, Brignone C, Guasti L, Steidl L, Ageno W. Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: A cohort study. *Vascular Medicine* 2017; 22: 518–24.

Elmi G, Allegri D, Aluigi L, Antignani PL, Aspide R, Camaggi V, DI Giulio R, Domanico A, Rinaldi ER, Martignani A, Palareti G. Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding. *Int Angiol* 2023; 42: 229–38.

Ferrara F, Meli F, Amato C, Cospite V, Raimondi F, Novo G, Novo S. Optimal Duration of Treatment in Surgical Patients With Calf Venous Thrombosis Involving One or More Veins. *Angiology* 2006; 57: 418–23.

Fujioka S, Ohkubo H, Kitamura T, Mishima T, Onishi Y, Tadokoro Y, Araki H, Matsushiro T, Yakuwa K, Miyamoto T, Torii S, Miyaji K. Risk Factors for Progression of Distal Deep Vein Thrombosis. *Circ J* 2020; 84: 1862–5.

Galanaud J-P, Righini M, Le Collen L, Douillard A, Robert-Ebadi H, Pontal D, Morrison D, Barrellier M-T, Diard A, Guénnéguez H, Brisot D, Faïsse P, Accassat S, Martin M, Delluc A, Solymoss S, Kassis J, Carrier M, Quéré I, Kahn SR. Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study. *J Thromb Haemost* 2020; 18: 857–64.

Galanaud J-P, Sevestre-Pietri M-A, Bosson J-L, Laroche J-P, Righini M, Brisot D, Boge G, van Kien A, Gattolliat O, Bettarel-Binon C, Gris J-C, Genty C, Quere I. Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: Results from the OPTIMEV study. *Thromb Haemost* 2009; 102: 493–500.

Galanaud JP, Quenet S, Rivron-Guillot K, Quere I, Sanchez Muñoz-Torrero JF, Tolosa C, Monreal M. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11086 patients. *Journal of Thrombosis and Haemostasis* 2009; 7: 2028–34.

Galanaud JP, Sevestre MA, Genty C, Kahn SR, Pernod G, Rolland C, Diard A, Dupas S, Jurus C, Diamand JM, Quere I, Bosson JL. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. *Journal of Thrombosis and Haemostasis* Blackwell Publishing Ltd; 2014; 12: 436–43.

Guarnera G, Abeni D, Antignani PL, Apollonio A, Conti F, Mollo PL, Murgiano A, Ofria F, Ruggeri M. Update on distal deep venous thrombosis. Reports of a multicenter study. *Int Angiol* 2014; 33: 560–4.

Hirko MK, Karthikeshwar Kasirajan -y, Turner JJ, Jeffrey Rubin t--and R. Vascular Surgery VOLUME 33 MAY/JUNE 1999 NUMBER 3 C). Westminster Publications, Inc; 1999.

Ho P, Lim HY, Chua CC, Sleeman M, Tacey M, Donnan G, Nandurkar H. Retrospective review on isolated distal deep vein thrombosis (IDDVT) — A benign entity or not? *Thromb Res* 2016; 142: 11–6.

Horner D, Hogg K, Body R, Nash MJ, Baglin T, Mackway-Jones K. The Anticoagulation of Calf Thrombosis (ACT) Project. *Chest* 2014; 146: 1468–77.

Huang Z, Sun H, Li D, Cai Z, Chen M, Ma S, Xu J, Ma R. Follow-up study of isolated calf muscular vein thrombosis for anticoagulant therapy after primary hip and knee arthroplasty. *Arch Orthop Trauma Surg* 2024; 144: 7–13.

Jørgensen CT, Tavoly M, Førsund E, Pettersen HH, Tjønnfjord E, Ghanima W, Brækkan SK. Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital. *Journal of Thrombosis and Haemostasis* 2023; 21: 2824–32.

Kim SM. Clinical presentation of isolated calf deep vein thrombosis in inpatients and prevalence of associated pulmonary embolism. *J Vasc Surg Venous Lymphat Disord* 2022; 10: 1037–43.

Kuczmik W, Wysokinski WE, Macedo T, Froehling D, Daniels P, Casanegra A, Houghton D, Vlazny D, Meverden R, Lang T, White L, Hodge D, McBane RD. Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies. *Mayo Clin Proc* 2021; 96: 1184–92.

Labropoulos N, Kang SS, Mansour MA, Giannoukas AD, Moutzouros V, Baker WH. Early thrombus remodelling of isolated calf deep vein thrombosis. *Eur J Vasc Endovasc Surg* 2002; 23: 344–8.

LAGERSTEDT C. NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSIS. *The Lancet* 1985; 326: 515–8.

Lautz TB, Abbas F, Walsh SJN, Chow C, Amaranto DJ, Wang E, Blackburn D, Pearce WH, Kibbe MR. Isolated Gastrocnemius and Soleal Vein Thrombosis. *Ann Surg* 2010; 251: 735–42.

Li AY, Woulfe T, Rolfe-Vyson V, Rowland V, Simpson D, Merriman E. Management and outcomes of axial isolated distal deep vein thrombosis at North Shore Hospital, New Zealand: a retrospective audit. *Intern Med J* 2015; 45: 177–82.

Lohr JM, James K V., Deshmukh RM, Hasselfeld KA. Calf vein thrombi are not a benign finding. *The American Journal of Surgery* 1995; 170: 86–90.

Luo X, Zhang L, Hou C, Li P, Wu S, Wang Z, Yang E, Cui Y, Sun N, Yu Y, An Z, Jin J, Qin Z. Hospitalized patients with isolated distal deep vein thrombosis: anticoagulation therapy or not? *Thromb J* 2022; 20: 52.

Masuda EM, Kessler DM, Kistner RL, Eklof B, Sato DT. The natural history of calf vein thrombosis: Lysis of thrombi and development of reflux. *J Vasc Surg* 1998; 28: 67–74.

Merriman E, Chunilal S, Brighton T, Chen V, McRae S, Ockelford P, Curnow J, Tran H, Chong B, Smith M, Royle G, Crowther H, Slocombe A, Tran H. Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER study). *Thromb Res* Elsevier Ltd; 2021; 207: 33–9.

Mo M, Fukuda I, Nakamura M, Yamada N, Takayama M, Maeda H, Yamashita T, Ikeda T, Yamazaki T, Okumura Y, Hirayama A. Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J'xactly, in Japan. *Phlebology: The Journal of Venous Disease* 2023; 38: 4–15.

Parisi R, Visonà A, Camporese G, Verlato F, Lessiani G, Antignani PL, Palareti G. Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. *Int Angiol* 2009; 28: 68–72.

Pasha AK, Kuczmik W, Wysokinski WE, Casanegra AI, Houghton D, Vlazny DT, Mertzig A, Hirao-Try Y, White L, Hodge D, McBane II R. Calf vein thrombosis outcomes comparing patients with and without cancer. *J Thromb Thrombolysis* 2021; 51: 1059–66.

Pellegrini VD, Langhans MJ, Totterman S, Marder VJ, Francis CW. Embolic complications of calf thrombosis following total hip arthroplasty. *J Arthroplasty* 1993; 8: 449–57.

Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel J-P. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis. *Circulation* 2001; 103: 2453–60.

Poudel SK, Park DY, Jia X, Wilks M, Pinkava V, O'Brien M, Tripp B, Song J, McCrae KR, Khorana AA, Angelini DE. Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. *Journal of Thrombosis and Haemostasis* 2020; 18: 651–9.

Righini M, Galanaud J-P, Guenneguez H, Brisot D, Diard A, Faisse P, Barrellier M-T, Hamel-Desnos C, Jurus C, Pichot O, Martin M, Mazzolai L, Choquenet C, Accassat S, Robert-Ebadi H, Carrier M, Le Gal G, Mermillod B, Laroche J-P, Bounameaux H, et al. Anticoagulant therapy for symptomatic calf deep vein

thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. *Lancet Haematol* 2016; 3: e556–62.

Saarinen JP, Domonyi K, Zeitlin R, Salenius J-P. Postthrombotic syndrome after isolated calf deep venous thrombosis: the role of popliteal reflux. *J Vasc Surg* 2002; 36: 959–64.

Sales CM, Haq F, Bustami R, Sun F. Management of isolated soleal and gastrocnemius vein thrombosis. *J Vasc Surg* Mosby Inc.; 2010; 52: 1251–4.

Sartori M, Iotti M, Camporese G, Siragusa S, Imberti D, Bucherini E, Corradini S, Ageno W, Prandoni P, Ghirarduzzi A. Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study. *Am J Hematol* 2024; 99(5):854-861.

Sartori M, Migliaccio L, Favaretto E, Palareti G, Cosmi B. Two years outcome of isolated distal deep vein thrombosis. *Thromb Res* 2014; 134: 36–40.

Schwarz T, Buschmann L, Beyer J, Halbritter K, Rastan A, Schellong S. Therapy of isolated calf muscle vein thrombosis: A randomized, controlled study. *J Vasc Surg* 2010; 52: 1246–50.

Schwarz T, Schmidt B, Beyer J, Schellong SM. Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. *Blood Coagulation & Fibrinolysis* 2001; 12: 597–9.

Sharpe RP, Gupta R, Gracias VH, Pryor JP, Pieracci FM, Reilly PM, Schwab CW. Incidence and Natural History of Below-Knee Deep Venous Thrombosis in High-Risk Trauma Patients. *The Journal of Trauma: Injury, Infection, and Critical Care* 2002; 53: 1048–52.

Solis MM, Ranval TJ, Nix ML, Eidt JF, Nelson CL, Ferris EJ, Lavender RC. Is anticoagulation indicated for asymptomatic postoperative calf vein thrombosis? *J Vasc Surg* Elsevier BV; 1992; 16: 0414–9.


Sule AA, Chin TJ, Handa P, Earnest A. Should symptomatic, isolated distal deep vein thrombosis be treated with anticoagulation?. Int J Angiol. 2009;18(2):83-87.

Utter GH, Dhillon TS, Salcedo ES, Shouldice DJ, Reynolds CL, Humphries MD, White RH. Therapeutic Anticoagulation for Isolated Calf Deep Vein Thrombosis. *JAMA Surg* 2016; 151: e161770.

Vlazny DT, Pasha AK, Kuczmik W, Wysokinski WE, Bartlett M, Houghton D, Casanegra AI, Daniels P, Froehling DA, White LJ, Hodge DO, McBane RD. Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis. *Journal of Thrombosis and Haemostasis* 2021; 19: 2206–15.

Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D, Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, et al. Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial. *Circulation* Ovid Technologies (Wolters Kluwer Health); 2023; 148(21):1665-1676.


Supplementary Figure 1. Recurrent deep vein thrombosis sorted by the duration of anticoagulation



Supplementary Figure 2. Recurrent deep vein thrombosis in patients receiving therapeutic dose of anticoagulation, sorted by the duration of anticoagulation

Study	Events Total	Proportion 95%-CI Weight
treatment = Long Ageno W, 2019 Ageno W. et al, 2022 Ferrara F et al., 2006 Ho P, 2016 Horner D, 2014 Lagerstedt, 1985 Li AY et al, 2015 Sule AA, 2009 Pinede L, 2001 Random effects mode Heterogeneity: I ² = 78%, 3		0.03 [0.02; 0.06] 5.0% 0.12 [0.08; 0.17] 5.4% 0.00 [0.00; 0.04] 1.8% 0.11 [0.07; 0.17] 5.2% 0.00 [0.00; 0.10] 1.7% 0.00 [0.00; 0.14] 1.7% 0.01 [0.00; 0.02] 4.1% 0.00 [0.00; 0.32] 1.7% 0.07 [0.03; 0.14] 4.7% 0.04 [0.02; 0.08] 31.4%
treatment = Short Asonitis K, 2020 Astermark, 1998 Merriman E, 2021 Pinede L, 2001 Righini M, 2016 Sule AA, 2009 Ageno W. et al, 2022 Ferrara F et al., 2006 Li AY et al, 2015 Random effects mode Heterogeneity: I ² = 90%, 4		0.05 [0.02; 0.11] 4.7% 0.09 [0.05; 0.15] 5.1% 0.02 [0.01; 0.04] 4.4% 0.04 [0.01; 0.09] 4.4% 0.03 [0.01; 0.08] 4.4% 0.00 [0.00; 0.30] 1.7% 0.19 [0.14; 0.25] 5.5% 0.31 [0.23; 0.41] 5.4% 0.04 [0.01; 0.13] 3.6% 0.07 [0.03; 0.14] 39.1%
treatment = Mixed Barco S, 2017 Lohr A. et al,1995 Lautz TB et al., 2010 Brateanu A. et al., 2016 Random effects mode Heterogeneity: I ² = 56%, 4	48 554	0.08 [0.05; 0.12] 5.3% 0.13 [0.05; 0.32] 4.0% 0.12 [0.08; 0.18] 5.4% 0.04 [0.02; 0.09] 4.7% 0.09 [0.05; 0.14] 19.3%
Saarinen 2002 Ageno W, 2019 Random effects mode Heterogeneity: $I^2 = 92\%$,		0.09 [0.04; 0.17] 4.8% 0.02 [0.01; 0.03] 5.3% 0.04 [0.01; 0.16] 10.2%
Random effects mode Prediction interval Heterogeneity: $I^2 = 88\%$, Test for subgroup difference		0.06 [0.04; 0.09] 100.0% [0.01; 0.32]

Supplementary Figure 3. Recurrent deep vein thrombosis in patients receiving intermediate dose of anticoagulation, sorted by the duration of anticoagulation



Supplementary Figure 4. Recurrent deep vein thrombosis in patients receiving prophylactic dose of anticoagulation, sorted by the duration of anticoagulation

Study	Events Total	P	roportion	95%-CI Weight
treatment = Short Elmi G. et al, 2023	5 86 -		0.06	[0.03; 0.13] 48.3%
treatment = Mixed Lautz TB et al., 2010	13 48		0.27	[0.17; 0.41] 51.7%
Random effects model Heterogeneity: $I^2 = 90\%$, τ Test for subgroup difference	2 = 1.4514, p < 0.0	p1 < 0.001.2	0.13	[0.03; 0.47] 100.0%


Supplementary Figure 5. Recurrent deep vein thrombosis in high-risk patients, sorted by the duration of anticoagulation

Study	Events Total	Proportion	95%-CI Weight
treatment = Long Ageno W. et al, 2022 Pasha AK et al, 2021 Random effects model Heterogeneity: $I^2 = 58\%$, τ		0.07	[0.08; 0.17] 24.9% [0.04; 0.11] 24.2% [0.06; 0.15] 49.2%
treatment = Short Merriman E, 2021 Righini M, 2016 Ageno W. et al, 2022	4 241 4 122 39 202 ———	0.03	[0.01; 0.04] 0.0% [0.01; 0.08] 0.0% [0.14; 0.25] 25.6%
treatment = Extended Yamashita Y et al, 2023	25 601 🛨	0.04	[0.03; 0.06] 25.2%
treatment = No Righini M, 2016	7 130	0.05	[0.03; 0.11] 0.0%
Random effects model Prediction interval Heterogeneity: $I^2 = 93\%$, τ Test for subgroup difference		0.09	[0.04; 0.18] 100.0% [0.00; 0.81]

Supplementary Figure 6. Recurrent deep vein thrombosis in low-risk patients, sorted by the duration of anticoagulation

Study	Events 7	Γotal		Propo	rtion	95%-CI	Weight
treatment = Long Ageno W. et al, 2022 Pasha AK et al, 2021	23 16	200 224				[0.08; 0.17] [0.04; 0.11]	0.0% 0.0%
treatment = Short Merriman E, 2021 Righini M, 2016 Ageno W. et al, 2022 Random effects mode Heterogeneity: $l^2 = 0\%$, τ^2		241 122 202 565 •			0.03 0.19	[0.01; 0.04] [0.01; 0.08] [0.14; 0.25] [0.01; 0.05]	30.3% 30.0% 0.0% 60.3 %
treatment = Extended Yamashita Y et al, 2023	25	601			0.04	[0.03; 0.06]	0.0%
treatment = No Righini M, 2016	7	130			0.05	[0.03; 0.11]	39.7%
Random effects mode Prediction interval Heterogeneity: $I^2 = 45\%$, 1 Test for subgroup differen	$z^2 = 0.1788,$	p = 0.16) <u>=</u> 20.10 0 .4 0.6	0.8	0.03	[0.02; 0.06] [0.00; 0.98]	100.0%

Supplementary Figure 7. Pulmonary embolism sorted by the duration of anticoagulation



Supplementary Figure 8. Pulmonary embolism in patients receiving therapeutic dose of anticoagulation, sorted by the duration of anticoagulation

Study	Events Total	Proportion	95%-Cl Weight
treatment = Short			
Asonitis K, 2020	0 119 🖳	0.00	[0.00; 0.03] 1.6%
Astermark, 1998	1 126 👚	0.01	[0.00; 0.04] 3.1%
Cox S. et al, 2014	3 38		[0.03; 0.21] 7.4%
Merriman E, 2021	0 241 ⊩		[0.00; 0.02] 1.6%
Pinede L, 2001	1 105 =		[0.00; 0.05] 3.1%
Righini M, 2016	2 122		[0.00; 0.06] 5.6%
Schwarz T, 2010	0 54 -		[0.00; 0.07] 1.6%
Sule AA, 2009	0 9 -		[0.00; 0.30] 1.5%
Ferrara F et al., 2006	3 96		[0.01; 0.09] 7.8%
Li AY et al, 2015	0 54		[0.00; 0.07] 1.6%
Random effects mode		0.02	[0.01; 0.04] 34.9%
Heterogeneity: $I^2 = 29\%$,	$\tau^- = 0.3599, p = 0.18$		
treatment = Mixed			
Barco S, 2017	6 202	0.03	[0.01; 0.06] 12.9%
Utter GH, 2016	4 243 +		[0.01; 0.04] 9.8%
Day T et al, 2022	1 33		[0.01; 0.15] 3.0%
Lautz TB et al., 2010	7 188		[0.02; 0.07] 14.1%
Belcaro G. et al, 1999	0 43	0.00	[0.00; 0.08] 1.6%
Random effects mode		0.03	[0.02; 0.04] 41.4%
Heterogeneity: $I^2 = 0\%$, τ^2	$p^2 = 0, p = 0.70$		
treatment Lang			
treatment = Long	0 06 -	0.00	[0 00, 0 04] 1 69/
Ferrara F et al., 2006 Ho P, 2016	0 96 - 		[0.00; 0.04] 1.6% [0.02; 0.08] 12.8%
Horner D, 2014	0 35		[0.00; 0.10] 1.6%
Huang Z, 2023	0 51 -		[0.00; 0.07] 1.6%
Li AY et al, 2015	0 400 -		[0.00; 0.01] 1.6%
Sule AA, 2009	0 8		[0.00; 0.32] 1.5%
Pinede L, 2001	1 92 =		[0.00; 0.06] 3.1%
Random effects mode			[0.01; 0.04] 23.7%
Heterogeneity: $I^2 = 32\%$,		3.02	
.			FO. 00. 0.007. 100.007
Random effects mode	1 35 2506 ♦	0.02	[0.02; 0.03] 100.0%
Prediction interval	2 0 0004 = 000		[0.01; 0.05]
Heterogeneity: $I^2 = 13\%$,		1) 0 15 0 0 0 0 5 0 0	
iest for subgroup differen	ces: $\chi_2^2 = 1.78$, df $\oplus 20005004$	1) 0.15 0.2 0.25 0.3	

Supplementary Figure 9. Pulmonary embolism in patients receiving intermediate dose of anticoagulation, sorted by the duration of anticoagulation

Study	Events Total	Proportion	95%-CI Weight
treatment = Short Donadini MP, 2016 Parisi R, 2009 Random effects model Heterogeneity: $I^2 = 74\%$, a		0.00	[0.03; 0.08] 62.1% [0.00; 0.02] 37.9% [0.00; 0.20] 100.0%
Random effects model Heterogeneity: $I^2 = 74\%$, τ Test for subgroup difference		— 0.02	[0.00; 0.20] 100.0%

Supplementary Figure 10. Pulmonary embolism in patients receiving prophylactic dose of anticoagulation, sorted by the duration of anticoagulation

Study	Events Total	Proportion	95%-CI Weight
treatment = Short Pellegrini V, 1993	0 12	0.00	[0.00; 0.24] 16.6%
treatment = Mixed Lautz TB et al., 2010 Belcaro G. et al, 1999 Random effects model Heterogeneity: I ² = 38%, T		0.00	[0.01; 0.14] 66.2% [0.00; 0.04] 17.2% [0.00; 0.13] 83.4%
Random effects model Prediction interval Heterogeneity: $I^2 = 0\%$, τ^2 Test for subgroup difference			[0.01; 0.09] 100.0% [0.00; 0.98]

Supplementary Figure 11. Pulmonary embolism in high-risk patients, sorted by the duration of anticoagulation

Study	Events Total		Proportion	95%-CI Weight
treatment = Long Pasha AK et al, 2021	7 224		0.03	[0.02; 0.06] 52.7%
treatment = Extended Yamashita Y et al, 2023	3 601	-	0.00	[0.00; 0.01] 47.3%
Random effects model Heterogeneity: $I^2 = 86\%$, τ Test for subgroup difference	$p^2 = 1.4904, p < 0.01$	1< 0.001,03 0.05 0	0.01 .07	[0.00; 0.08] 100.0%

Supplementary Figure 12. Pulmonary embolism in low-risk patients, sorted by the duration of anticoagulation

Study	Events Total	Proportion	95%-CI Weight
treatment = Short Merriman E, 2021 Righini M, 2016 Schwarz T, 2010 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2		0.02 0.00	[0.00; 0.02] 6.2% [0.00; 0.06] 17.4% [0.00; 0.07] 6.1% [0.00; 0.03] 29.6%
treatment = Mixed Day T et al, 2022 Belcaro G. et al, 1999 Belcaro G. et al, 1999 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2		0.00 0.00	[0.01; 0.15] 10.6% [0.00; 0.08] 6.1% [0.00; 0.04] 6.1% [0.00; 0.06] 22.8%
treatment = No Righini M, 2016 Schwarz T, 2010 Day T et al, 2022 Belcaro G. et al, 1999 Random effects model Heterogeneity: I ² = 49%, τ		0.00 0.07 0.00	[0.00; 0.04] 10.8% [0.00; 0.07] 6.1% [0.03; 0.16] 24.5% [0.00; 0.08] 6.1% [0.01; 0.08] 47.5%
Random effects model Prediction interval Heterogeneity: $I^2 = 23\%$, τ Test for subgroup difference		0.02	[0.01; 0.03] 100.0% [0.00; 0.08]

${\bf Supplementary\ Figure\ 13.\ Proximal\ progression\ of\ thrombosis\ sorted\ by\ the\ duration\ of\ anticoagulation}$

Study	Events Total	Proportion 95%-CI Weight
treatment = Short Cox S. et al, 2014 Ferrara F et al., 2006 Hirko M, 1999 Li AY et al, 2015 Merriman E, 2021 Parisi R, 2009 Random effects model Heterogeneity: $l^2 = 89\%$, $\tau^2 = 100$	3 38 27 96 3 24 1 1 54 1 1 54 1 1 5 241 1 1 5 1 624 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.08 [0.03; 0.21] 3.0% 0.28 [0.20; 0.38] 4.1% 0.12 [0.04; 0.31] 3.0% 0.02 [0.00; 0.10] 1.9% 0.06 [0.04; 0.10] 4.0% 0.01 [0.00; 0.04] 2.7% 0.07 [0.02; 0.18] 18.7%
treatment = Long Ferrara F et al., 2006 Galanaud JP, 2014 Huang Z, 2023 Jørgensen CT, 2023 Poudel S, 2020 Random effects model Heterogeneity: $l^2 = 72\%$, $\tau^2 = 100$	7 96 4 485 0 51 21 475 3 91 35 1198 \Leftrightarrow = 0.5100, $p < 0.01$	0.07 [0.04; 0.14] 3.7% 0.01 [0.00; 0.02] 3.3% 0.00 [0.00; 0.07] 1.2% 0.04 [0.03; 0.07] 4.1% 0.03 [0.01; 0.09] 3.1% 0.03 [0.01; 0.06] 15.4%
treatment = No Fujioka, 2020 Horner D, 2014 Kim SM, 2022 Kuczmik W, 2021 Schwarz T, 2001 Utter GH, 2016 Luo X et al, 2022 Day T et al, 2022 Labropoulos N. et al, 2002 Lautz TB et al., 2010 Masuda EM et al, 1998 Random effects model Heterogeneity: I ² = 74%, τ ² s	25 119 — — — — — — — — — — — — — — — — — —	0.06 [0.03; 0.10] 4.0% 0.09 [0.03; 0.22] 3.0% 0.30 [0.11; 0.60] 2.7% 0.08 [0.04; 0.16] 3.7% 0.25 [0.13; 0.42] 3.6% 0.05 [0.02; 0.10] 3.7% 0.05 [0.02; 0.10] 3.7% 0.09 [0.04; 0.19] 3.4% 0.17 [0.08; 0.35] 3.4% 0.21 [0.15; 0.29] 4.1% 0.08 [0.02; 0.24] 2.6% 0.11 [0.07; 0.16] 37.9%
treatment = Extended Mo M, 2023	7 288 +	0.02 [0.01; 0.05] 3.7%
treatment = Mixed Sartori M, 2014 Utter GH, 2016 Luo X et al, 2022 Solis M. et al, 1992 Labropoulos N. et al, 2002 Lautz TB et al., 2010 Lautz TB et al., 2010 Random effects model Heterogeneity: $l^2 = 79\%$, $\tau^2 = 10$	9 48 ———————————————————————————————————	0.11 [0.06; 0.20] 3.8% 0.02 [0.01; 0.04] 3.3% 0.04 [0.02; 0.07] 4.0% 0.21 [0.08; 0.48] 2.9% 0.11 [0.03; 0.31] 2.6% 0.19 [0.10; 0.32] 3.7% 0.06 [0.04; 0.11] 4.0% 0.08 [0.04; 0.14] 24.2%
Prediction interval Heterogeneity: $I^2 = 84\%$, $\tau^2 = 84\%$		[0.01; 0.33]

Supplementary Figure 14. Post-thrombotic syndrome sorted by the duration of anticoagulation

Study	Events Total	Prop	ortion	95%-CI	Weight
treatment = Short Asonitis K, 2020 Sule AA, 2009 Galanaud 2020 Random effects model Heterogeneity: $I^2 = 90\%$, τ		- - -	0.11 0.29	[0.01; 0.08] [0.02; 0.43] [0.20; 0.39] [0.02; 0.44]	18.7% 9.6% 23.9% 52.2%
treatment = No Sule AA, 2009 Galanaud 2020 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2			0.32	[0.09; 0.45] [0.23; 0.42] [0.23; 0.40]	17.5% 24.1% 41.6%
treatment = Long Sule AA, 2009	0 8 -		0.00	[0.00; 0.32]	6.2%
Random effects model Prediction interval Heterogeneity: $I^2 = 80\%$, τ Test for subgroup difference	$p^2 = 0.6678, p < 0.0$	©p1= 0.28)0.3 0.4 0.5 0.6 0.7	0.16	[0.08; 0.31] [0.02; 0.72]	100.0%

$Supplementary\ Figure\ 15.\ Recurrent\ deep\ vein\ thrombosis\ in\ patients\ receiving\ different\ duration\ of\ anticoagulation$

Study	Experim Events		Co Events	ontrol Total	Risk Ratio	RR	95%-CI Weight
treatment = Long vs E Ageno W, 2019	9	272	19	1004	-	1.75	[0.80; 3.82] 25.1%
treatment = Short vs L Ageno W. et al, 2022 Ferrara F et al., 2006 Li AY et al, 2015 Pinede L, 2001 Sartori M, 2024 Random effects mode Heterogeneity: $I^2 = 52\%$, 1	39 30 2 2 14 87	96 54 105 130 585	3 2 5 33	202 96 400 92 130 920		4.94 0.88 2.80	[3.78; 983.41] 4.0% [0.84; 28.89] 8.7% [0.13; 6.10] 7.5%
					0.01 0.1 1 10 100		

Supplementary Figure 16. Recurrent deep vein thrombosis in patients receiving or not anticoagulation, sorted by the duration of anticoagulation

Study	Experimental Events Total		ntrol Total	Risk Ratio	RR	ç	95%-CI	Weight
treatment = Short vs N								
Elmi G. et al, 2023 Righini M, 2016	5 86 4 122	3 7	4 130		0.08 0.61	[0.03; [0.18;	0.22] 2.03]	18.0% 15.7%
Sule AA, 2009	0 9	0	18		0.01	[0.10,	2.00]	0.0%
Random effects mode Heterogeneity: $I^2 = 85\%$, a		10	152		0.21	[0.03;	1.60]	33.7%
Heterogeneity. 7 – 6576,	ι – 1.7990, <i>p</i> – 0	7.01						
treatment = Long vs N Kuczmik W, 2021	29 399	12	84	<u> </u>	0.51	[0.27;	0.96]	23.8%
Lagerstedt, 1985	0 23	8	28		0.06	[0.27,	1.22]	4.7%
Poudel S, 2020	10 91	0	5		- 11.55	[0.00; 603	-	0.6%
Sule AA, 2009	0 8	0 20	18		0.40	FO 40:	4 201	0.0%
Random effects mode Heterogeneity: $I^2 = 15\%$, a			135		0.40	[0.12;	1.36]	29.1%
treatment = Mixed vs I Lohr A. et al,1995	NO 3 23	38	169		0.58	[0.19;	1.73]	17.1%
Brateanu A. et al., 2016		24	309	=	0.55	[0.13;	1.31]	20.2%
Random effects mode		62	478	⇔	0.56	[0.28;	1.11]	37.2%
Heterogeneity: $I^2 = 0\%$, τ^2	= 0, p = 0.94							
				0.001 0.1 1 10 1000				

Supplementary Figure 17. Pulmonary embolism in patients receiving different duration of anticoagulation

Study	Experim Events			ntrol Total	Risk Ratio	RR	95%-Cl Weight
treatment = Short vs L Ferrara F et al., 2006 Li AY et al, 2015 Pinede L, 2001 Sartori M, 2024 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2	3 0 1 1 5	96 54 105 130 385	0 0 1 1 2	96 400 92 130 718	——————————————————————————————————————	7.00 0.88 1.00 1.73	[0.37; 133.70] 30.4% 0.0% [0.06; 13.81] 34.8% [0.06; 15.82] 34.7% [0.34; 8.79] 100.0%
Random effects mode Prediction interval Heterogeneity: $I^2 = 0\%$, τ^2 Test for subgroup differen	= 0, p = 0		2 = 0 (p = N	718	0.001 0.1 1 10 1000	1.73	[0.34; 8.79] 100.0% [0.00; 65923.82]


Supplementary Figure 18. Pulmonary embolism in patients receiving or not anticoagulation, sorted by the duration of anticoagulation

Study	Experime Events T			ntrol Total	Risk Ratio	RR	95%-CI Weight
treatment = Short vs not Cox S. et al, 2014 Pellegrini V, 1993 Righini M, 2016 Schwarz T, 2010 Sule AA, 2009 Random effects model Heterogeneity: $I^2 = 66\%$, τ^2	3 0 2 0 0 5	38 12 122 54 9 235 p = 0.	1 4 1 0 0 6	130 13 130 53 18 344		10.26 0.12 2.13	[1.10; 95.84] 11.7% [0.01; 2.04] 7.9% [0.20; 23.21] 10.6% 0.0% 0.0% [0.13; 18.17] 30.2%
treatment = Short vs Lo Ferrara F et al., 2006 Li AY et al, 2015 Pinede L, 2001 Sartori M, 2024	3 0 1 1	96 54 105 130	0 0 1 1	96 400 92 130		7.00 0.88 1.00	[0.37; 133.70] 0.0% 0.0% [0.06; 13.81] 0.0% [0.06; 15.82] 0.0%
treatment = Long vs not Horner D, 2014 Kuczmik W, 2021 Poudel S, 2020 Sule AA, 2009 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2	0 8 4 0	35 399 91 8 533	1 1 0 0 2	35 84 5 18		0.33 1.68 - 5.22 1.11	[0.01; 7.91] 6.7% [0.21; 13.29] 13.2% [0.00; 27975.56] 1.0% 0.0% [0.20; 6.03] 20.9%
treatment = Mixed vs n Utter GH, 2016 Luo X et al, 2022 Day T et al, 2022 Masuda EM et al, 1998 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2	4 4 1 0 9	243 288 33 28 592	6 1 4 0	141 138 58 26 363		0.39 1.92 0.44 0.54	[0.11; 1.35] 24.4% [0.22; 16.99] 12.2% [0.05; 3.77] 12.4% 0.0% [0.21; 1.43] 49.0%
					0.001 0.1 1 10 1000		

Supplementary Figure 19. Proximal progression of thrombosis in patients receiving different regimens of anticoagulation

Study	Experim Events		Co Events	ntrol Total	Risk Ratio	RR		95%-CI	Weight
treatment = Short vs Lo Ferrara F et al., 2006	ng 27	96	7	96	+	3.86	[1.77;	8.43]	36.8%
treatment = Mixed vs no Utter GH, 2016 Labropoulos N. et al, 200 Random effects model Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0\%$	2 2 6	19 262	5	141 29 170	0.001 1 1000	0.33 0.61 0.42	[0.10; [0.13; [0.16;	1.11] 2.83] 1.08]	33.1% 30.0% 63.2%

Supplementary Figure 20. Major bleeding sorted by the duration of anticoagulation



Supplementary Figure 21. Major bleeding in high-risk patients, sorted by the duration of anticoagulation

Study	Events	Total	Proportion	95%-CI V	Neight
treatment = Long Ageno W. et al, 2022 Pasha AK et al, 2021 Random effects model Heterogeneity: I ² = 81%, τ	14	424	0.06	. , .	8.6% 39.2% 47.8%
treatment = Extended Yamashita Y et al, 2023	50	601	0.08	[0.06; 0.11]	43.6%
treatment = Short Ageno W. et al, 2022	0	202 ⊩	0.00	[0.00; 0.02]	8.6%
Random effects model Prediction interval Heterogeneity: $I^2 = 77\%$, τ Test for subgroup difference	² = 0.4627,	1, p < 0.01	0.04	[0.02; 0.10] 1 [0.00; 0.60]	100.0%

Supplementary Figure 22. Major bleeding in low-risk patients, sorted by the duration of anticoagulation

Study	Events Total	Proportion 95%-Cl	Weight
treatment = Short Merriman E, 2021 Righini M, 2016 Schwarz T, 2010 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2		0.00 [0.00; 0.02] 0.01 [0.00; 0.04] 0.00 [0.00; 0.07] 0.01 [0.00; 0.02]	25.0% 12.5%
treatment = Mixed Day T et al, 2022	0 33	0.00 [0.00; 0.10]	12.4%
treatment = No Schwarz T, 2010 Day T et al, 2022 Righini M, 2016 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2		0.00 [0.00; 0.07] 0.00 [0.00; 0.06] 0.00 [0.00; 0.03] 0.01 [0.00; 0.03]	12.5% 12.6%
Random effects mode Prediction interval Heterogeneity: $I^2 = 0\%$, τ^2 Test for subgroup differen		0.01 [0.00; 0.02] [0.00; 0.02]	

Supplementary Figure 23. Clinically relevant non-major bleeding events sorted by the duration of anticoagulation

Study	Events	Total	Proportion	95%-CI	Weight
treatment = Short Asonitis K, 2020 Astermark, 1998 Guarnera G, 2014 Merriman E, 2021 Parisi R, 2009 Righini M, 2016	0 0 0 5 0 4	126 110 241 171	0.00 0.00 0.02 0.00	[0.00; 0.03] [0.00; 0.03] [0.00; 0.03] [0.01; 0.05] [0.00; 0.02] [0.01; 0.08]	1.2% 1.2% 1.2% 5.1% 1.2% 4.6%
Sartori M, 2024 Ferrara F et al., 2006 Random effects mode Heterogeneity: $I^2 = 11\%$, attreatment = Long		96 ► 1115 ♦	0.01 0.00	[0.00; 0.04] [0.00; 0.04] [0.01; 0.03]	2.0% 1.2% 17.6%
Dentali F. et al, 2017 Huang Z, 2023 Jørgensen CT, 2023 Kuczmik W, 2021 Pasha AK et al, 2021 Pasha AK et al, 2021 Poudel S, 2020 Ferrara F et al., 2006 Sartori M, 2024 Random effects mode Heterogeneity: I ² = 77%, 3		51	0.00 0.03 0.02 0.07 0.05 0.12 0.00 0.01	[0.05; 0.11] [0.00; 0.07] [0.02; 0.05] [0.01; 0.04] [0.04; 0.11] [0.03; 0.07] [0.07; 0.20] [0.00; 0.04] [0.00; 0.04] [0.03; 0.07]	7.3% 1.2% 7.0% 5.8% 6.9% 7.3% 6.3% 1.2% 2.0% 45.0%
treatment = No Righini M, 2016 Kuczmik W, 2021 Utter GH, 2016 Day T et al, 2022 Solis M. et al, 1992 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2		84	0.02 0.02 0.00 0.00	[0.00; 0.03] [0.01; 0.08] [0.01; 0.06] [0.00; 0.06] [0.00; 0.12] [0.01; 0.04]	1.2% 3.2% 4.1% 1.2% 1.2% 10.8%
treatment = Mixed Utter GH, 2016 Vlazny DT et al, 2021 Day T et al, 2022 Solis M. et al, 1992 Random effects mode Heterogeneity: I ² = 43%, 3		33 14 1036 C	0.05 0.03 - 0.07	[0.06; 0.13] [0.04; 0.07] [0.01; 0.15] [0.01; 0.31] [0.04; 0.09]	7.2% 7.6% 2.0% 1.9% 18.8%
Yamashita Y et al, 2023 Random effects mode Prediction interval		601 		[0.06; 0.11] [0.03; 0.05] [0.01; 0.11]	7.8% 100.0%
Heterogeneity: $I^2 = 70\%$,	$x^2 = 0.326$ ces: $\chi_4^2 = 3$	2, <i>p</i> < 0.01	3	[5.5., 4]	

Supplementary Figure 24. Clinically relevant non-major bleeding in high-risk patients, sorted by the duration of anticoagulation

Study	Events Total		Proportion	95%-CI Weight
treatment = Long Pasha AK et al, 2021	16 224		0.07	[0.04; 0.11] 24.5%
treatment = Extended Yamashita Y et al, 2023	50 601	-	0.08	[0.06; 0.11] 75.5%
Random effects model Heterogeneity: $I^2 = 0\%$, τ^2 Test for subgroup difference	= 0, p = 0.58	=010(\$0±006508)070.080.09 0.1 0.1		[0.06; 0.10] 100.0%

Supplementary Figure 25. Clinically relevant non-major bleeding in low-risk patients, sorted by the duration of anticoagulation

Study	Events Total	Proportion 95%-CI We	eight
treatment = Short Merriman E, 2021 Righini M, 2016 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2		0.03 [0.01; 0.08] 3	5.6% 6.1% 1.7%
treatment = Mixed Day T et al, 2022 treatment = No	1 33	0.03 [0.01; 0.15]	9.0%
Day T et al, 2022 Righini M, 2016 Random effects mode Heterogeneity: $I^2 = 0\%$, τ^2		0.00 [0.00; 0.03]	4.6% 4.6% 9.3%
Random effects mode Prediction interval Heterogeneity: $I^2 = 0\%$, τ^2 Test for subgroup differen		0.02 [0.01; 0.04] 10 [0.01; 0.06]	0.0%


Supplementary Figure 26. Major bleeding in patients receiving different regimens of anticoagulation


Study	Experim Events		Co Events	ntrol Total	Risk Ratio	RR	95%-CI W	eight/
treatment = Short vs L Ageno W. et al, 2022 Li AY et al, 2015 Pinede L, 2001 Sartori M, 2024 Random effects model Heterogeneity: I ² = 82%, T	39 2 1 1 43	202 54 105 130 491 , p < 0	0 4 6 5 15	200 400 92 130 822		3.70 [0 0.15 [0 0.20 [0	.69; 19.74] 1 0.02; 1.19] 1 0.02; 1.69] 1	12.5% 17.4% 15.4% 15.3% 60.6%
treatment = Long vs North Kuczmik W, 2021 Poudel S, 2020 Random effects model Heterogeneity: $I^2 = 0\%$, τ^2	16 4 20	399 91 490 51	12 0 12	84 5 89	<u>+</u> *	- 5.22 [0.0	0; 27975.56]	21.3% 2.6% 23.9%
treatment = Short vs N Righini M, 2016	0 1	122	7	130	-	0.15 [0	0.02; 1.22] 1	15.5%
					0.001 0.1 1 10 1000			


Supplementary Figure 27. Clinically relevant non-major bleeding in patients receiving different regimens of anticoagulation

Study	Experimental Events Total E	Control vents Total	Risk Ratio	RR	95%-CI Weight
treatment = Long vs N Kuczmik W, 2021	7 399	2 84		0.74 [0.16; 3.48] 27.9%
treatment = Short vs L Sartori M, 2024	ong 1 130	1 130		1.00 [0	0.06; 15.82] 8.8%
Utter GH, 2016 Day T et al, 2022 Solis M. et al, 1992 Random effects mode Heterogeneity: $l^2 = 0\%$, τ^2	21 243 1 33 1 14 1 23 290	3 141 0 58 0 28 3 227	*	— 3.76 [0 — 4.00 [0	1.23; 13.38] 47.4% 0.20; 71.34] 7.8% 0.23; 70.60] 8.2% .43; 11.26] 63.3%
			0.1 0.51 2 10		


Egger test = p-value, 0.08








Egger test = p-value, 0.44




Logit Transformed Proportion

Egger test = p-value, < 0.05



Logit Transformed Proportion

Egger test = p-value < 0.05



Logit Transformed Proportion

Supplementary Table 1. Characteristics of included studies

First author, year	Study design	Symptomatic IDDVT	Patients' class of risk	Main risk factors	Treatment du	ration cohorts	Dosage AC	Follow- up
Ageno W, 2019	PC	No	NA	Mixed	Long, 272	Extended, 1004	Therapeutic	12 months
Ageno W, 2022	RCT	Yes	High	Mixed	Long, 200	Short, 202	Therapeutic	24 months
Asonitis K, 2020	RC	No	NA	Not reported	Short, 119	-	Therapeutic	3 months
Astermark, 1998	PC	No	NA	Mixed	Short, 126	-	Therapeutic	24 months
Barco S, 2017	RC	Yes	NA	Mixed	Mixed, 202	-	Therapeutic	7.6 years
Belcaro G, 1997	RCT	Not reported	Low	Mixed	Mixed, 130	None, 44	Therapeutic, 43	6 months
Beleato G, 1997	KC1	Not reported		Wilked	Wilked, 150	None, 44	Prophylactic, 87	
Brateanu A, 2016	RC	Yes	NA	Mixed	Mixed, 141	None, 309	Therapeutic	3 months
Brewster AC, 2021	RC	No	NA	Mixed	No, 182	-		1 month
Cox S, 2014	RC	No	NA	Unprovoked	Short, 38	None, 130	Therapeutic	1 month
Day T, 2022	RC	No	Low	Surgery/trauma/immobilization	Mixed, 33	None, 58	Therapeutic	Not reported
Dentali F, 2017	PC	Yes	NA	Cancer	Long, 305	None, 3	Mixed	13.9 months
Donadini MP, 2016	PC	Yes	NA	Mixed	Short, 280	-	Intermediate	42.3 month
Elmi G, 2023	PC	Mixed	NA	Surgery/trauma/immobilization	Short, 86	-	Prophylactic	1 month
Ferrara F, 2006	RCT	Yes	NA	Surgery/trauma/immobilization	Long, 96	Short, 96	Therapeutic	4 months
Fujioka, 2020	RC	Mixed	NA	Mixed	No, 212	-		3 months
Galanaud JP, 2009	PC	Yes	NA	Mixed	Mixed, 1921	-	Not reported	3 months
Galanaud JP, 2014	PC	Yes	NA	Mixed	Long, 485	-	Mixed	3 years
Galanaud J, 2020	RCT	Yes	NA	Mixed	Short, 87	None, 91	Therapeutic	1 year
Guarnera G, 2014	PC	NA	NA	Mixed	Short, 110	-	Not reported	Not reported
Hirko M, 1999	RC	No	NA	Surgery/trauma/immobilization	Short, 24	None, 4	Therapeutic	1 year
Ho P, 2016	RC	Mixed	NA	Mixed	Long, 151	None, 4	Therapeutic	24 months
Horner D, 2014	RCT	Yes	NA	Mixed	Long, 35	None, 35	Therapeutic	3 months
Huang Z, 2023	PC	No	NA	Surgery/trauma/immobilization	Long, 51	-	Therapeutic	3 months

							1	
Jørgensen CT, 2023	PC	Yes	NA	Mixed	Long, 475	-	Not reported	4.7 years
Kim SM, 2022	RC	Not reported	NA	Mixed	Mixed, 96	None, 10	Not reported	15.5 months
Kuczmik W, 2021	PC	Mixed	NA	Mixed	Long, 399	None, 84	Not reported	8 months
Labropoulos N, 2002	PC	Yes	NA	Mixed	Mixed, 19	None, 29	Therapeutic	1 month
Lagerstedt, 1985	RCT	Yes	NA	Not reported	Long, 23	None, 28	Therapeutic	3 months
Lautz TB, 2010	PC	PC Mixed	NA	Mixed	Mixed, 236	None, 119	Prophylactic, 48	7.5 months
Lautz 1B, 2010	10	Wilked	IVA	IVIIACU	Wilked, 230	None, 119	Therapeutic, 188	
Li AY, 2015	RC	Mixed	NA	Not reported	Long, 400	Short, 54	Therapeutic	3 months
Lohr A,1995	PC	Mixed	NA	Mixed	Mixed, 23	None, 169	Therapeutic	1 month
Luo X, 2022	RC	Mixed	NA	Mixed	Mixed, 288	None, 138	Mixed	11.6 months
Masuda EM, 1998	RC	Mixed	NA	Mixed	Mixed, 28	None, 26	Not reported	3 years
Merriman E, 2021	PC	Yes	Low	Mixed	Short, 241	-	Therapeutic	3 months
Mo M, 2023	PC	Mixed	NA	Mixed	Extended, 288	-	Mixed	21.3 months
Parisi R, 2009	PC	Yes	NA	Mixed	Short, 171	-	Intermediate	3 months
Pasha AK, 2021	RC	Not reported	High	Cancer	Long, 224	-	Mixed	9 months
1 asila AIX, 2021	KC		NA	Mixed	Long, 521	-	Mixed	8 months
Pellegrini V, 1993	RCT	No	NA	Surgery/trauma/immobilization	Short, 12	None, 13	Prophylactic	13 months
Pinede L, 2001	RCT	Yes	NA	Mixed	Short, 105	Long, 92	Therapeutic	12 months
Poudel S, 2020	PC	Mixed	NA	Cancer	Long, 91	None, 5	Not	2 years
Righini M, 2016	RCT	Yes	Low	Mixed	Short, 122	None, 130	Therapeutic	3 months
Sales C, 2010	RC	Yes	NA	Surgery/trauma/immobilization	Mixed, 76	None, 65	Therapeutic	Not reported
Sartori M, 2014	PC	Yes	NA	Mixed	Mixed, 88	-	Mixed	24 months
Sartori M, 2024	RCT	Yes	NA	Not reported	Short, 130	Long, 130	Mixed	6 months
Schwarz T, 2001	RCT	Yes	NA	Mixed	Short, 52	None, 32	Therapeutic	3 months
Schwarz T, 2010	RCT	Yes	Low	Mixed	Short, 54	None, 53	Therapeutic	3 months
Sharpe RP, 2002	PC	NA	NA	Surgery/trauma/immobilization	Short, 85	-	Not reported	1 month
Solis M, 1992	PC	No	NA	Surgery/trauma/immobilization	Mixed, 14	None, 28	Therapeutic	Not reported
Sule AA, 200[36]	RC	Yes	NA	Mixed	Short, 9	None, 18	Therapeutic	7 months

					Long, 8			
Saarinen 2002	RC	Mixed	NA	Mixed	Extended, 82	-	Therapeutic	8.4 years
Utter GH, 2016	RC	Mixed	NA	Mixed	Mixed, 243	None, 141	Therapeutic	6 months
Vlazny DT, 2021	RC	No	NA	Mixed	Mixed, 746	-	Mixed	8.4 months
Yamashita Y, 2023	RCT	No	High	Cancer	Extended, 601	-	Mixed	1 year

Abbreviations: AC, anticoagulation; IDDVT, isolated distal deep vein thrombosis; NA, not available; RCT, randomized controlled trial, PC, observational prospective cohort; RC, observational retrospective cohort. Legend: short (<6 weeks), long (6-12 weeks), extended (>12 weeks), and mixed (mixed duration).

Supplementary Table 2. Pooled prevalence of the outcomes sorting studies by the type of anticoagulant therapy

Outcomes	Incidence (95% confidence intervals)	Number of studies	Heterogeneity
Recurrent deep vein thrombosis			
DOACs	8% (3% to 17%)	3	94%
VKAs	6% (3% to 17%)	6	86%
LMWHs	6% (3% to 10%)	10	82%
Pulmonary embolism			
DOACs	1% (0% to 4%)	2	76%
VKAs	2% (1% to 5%)	7	21%
LMWHs	2% (1% to 4%)	11	47%
Proximal progression			
DOACs	2% (1% to 5%)	1	Not applicable
VKAs	12% (5% to 28%)	2	81%
LMWHs	3% (0% to 28%)	3	88%
Post-thrombotic syndrome			
VKAs	6% (0% to 50%)	1	Not applicable
LMWHs	11% (2% to 44%)	3	90%
Major bleeding			
DOACs	2% (0% to 12%)	3	89%
VKAs	0% (0% to 2%)	2	0%
LMWHs	2% (1% to 3%)	10	11%
Clinically relevant non-major bleeding			
DOACs	8% (1% to 11%)	1	Not applicable
VKAs	1% (0% to 2%)	3	0%
LMWHs	1% (0% to 3%)	5	32%

Abbreviations: DOACs, direct oral anticoagulants; LMWHs, low molecular weight heparins; VKAs, vitamin K antagonists.

Supplementary Table 3. Pooled prevalence of the outcomes in randomized trials and prospective cohort studies

Outcomes	Incidence (95% confidence intervals)	Number of studies	Heterogeneity
Recurrent deep vein thrombosis	8% (6% to 11%)	38	92%
Pulmonary embolism	2% (2% to 3%)	42	60%
Proximal progression	7% (5% to 11%)	21	87%
Post-thrombotic syndrome	30% (24% to 38%)	2	0%
Major bleeding	2% (1% to 3%)	29	77%
Clinically relevant non-major bleeding	3% (2% to 5%)	21	75%

Supplementary Table 4. Risk ratios of the outcomes (sorted by type of treatment allocations) in randomized trials and prospective cohort studies

Outcomes, num	Incidence (95% confidence intervals)	Number of studies	Heterogeneity
Recurrent deep vein thrombosis			
Short vs Long therapy	2.52 (0.97 to 6.54)	5	59%
Long vs Extended therapy	1.75 (0.80 to 3.82)	1	Not applicable
Short vs No therapy	0.21 (0.03 to 1.60)	3	85%
1 0	0.21 (0.03 to 1.00) 0.40 (0.12 to 1.36)		15%
Long vs No therapy	0.40 (0.12 to 1.30)	4	1370
Pulmonary embolism	1.52 (0.24 . 0.50)		00/
Short vs Long therapy	1.73 (0.34 to 8.79)	3	0%
Short vs No therapy	0.56 (0.03 to 9.61)	2	57%
Long vs No therapy	1.11 (0.20 to 6.03)	3	0%
Proximal progression			
Short vs Long therapy	3.86 (1.77 to 8.43)	1	Not applicable
Major bleeding			
Short vs Long therapy	1.18 (0.03 to 43.29)	3	86%
Chart wa Na tharran	0.15 (0.02 to 1.22)	1	Not annlicable
Short vs No therapy	0.15 (0.02 to 1.22)		Not applicable
Long vs No therapy	0.29 (0.14 to 0.58)	2	0%
Clinically relevant non-major bleeding			
Short vs Long therapy	1.0 (0.06 to 15.82)	1	Not applicable
Long vs No therapy	0.74 (0.16 to 3.48)	1	Not applicable

Supplementary Table 5. Pooled prevalence of the outcomes in high quality studies published since 2009

Outcomes	Incidence (95% confidence intervals)	Number of studies	Heterogeneity
Recurrent deep vein thrombosis	6% (4% to 10%)	11	93%
Pulmonary embolism	2% (1% to 3%)	10	71%
Proximal progression	8% (2% to 27%)	3	86%
Post-thrombotic syndrome	17% (6% to 39%)	2	91%
Major bleeding	2% (1% to 4%)	9	88%
Clinically relevant non-major bleeding	5% (3% to 7%)	7	73%

Supplementary Table 6. Patients' risk definitions

First author, year	Patients' Risk Definition
Ageno W., 2022	High-risk patients: age > 50 years; history of VTE; unprovoked IDDVT;
	secondary IDDVT that resulted in persistently reduced mobilisation; chronic
	underlying comorbidities (e.g., inflammatory bowel disease); known
	thrombophilia; IDDVT that involves the popliteal trifurcation; multiple and/or
	bilateral IDDVT. Cancer patients were excluded. All other patients were
	considered at low risk.
Merriman E., 2021	High-risk patients were excluded, defined as: patients with bilateral IDDVT,
	duration of symptoms for more than two weeks, DVT involving trifurcation or
	more proximal leg veins on imaging, prior DVT, active malignancy (present at
	time of diagnosis, or on treatment, or treatment completed within three months),
	ongoing risk factors for propagation, such as ongoing immobility (>50% of the day
	in bed or ≥72 h), plaster cast or non-weight bearing.
Righini M., 2016	The study excluded high-risk patients, defined as: patients with previous
	documented VTE, inpatients, and patients with cancer.

Abbreviations: DVT, deep vein thrombosis; IDDVT, isolated distal deep vein thrombosis; VTE, venous thromboembolism.

Supplementary Table 7. Anticoagulant dose definitions

First author, year	Anticoagulant Dose Definition		
Ageno W., 2019	Therapeutic dose: the rivaroxaban cohort included patients who received		
	rivaroxaban alone and those who had received heparin/fondaparinux for a		
	maximum of 48 hours before initiating rivaroxaban treatment (15 mg BID for 21		
	days followed by 20 mg OD).		
Ageno W., 2022	Therapeutic dose: rivaroxaban 15 mg BID for 3 weeks followed by rivaroxaban 20 mg OD for 3 weeks.		
Astonitis K., 2020	Therapeutic dose: enoxaparin 1.5 mg/kg/day for a 40-day period in the absence of		
1 1 1000	contra-indications.		
Astermark J., 1998	Therapeutic dose: UFH regimen was an initial, intravenous bolus injection of 5000		
	IU followed by 250 IU/kg subcutaneously BID; dalteparin regimen was 200		
Day T., 2022	IU/kg/day, followed by AVKs with a target INR between 2.0 and 3.0. Prophylactic dose: UFH 5000 IU BID, or enoxaparin 40 mg OD, or renally		
Day 1., 2022	adjusted dose equivalent.		
Dentali F., 2017	Full therapeutic or intermediate dose of parenteral antithrombotic therapy was used		
Dentan F., 2017	in the vast majority of patients. VKAs with a target INR between 2.0 and 3.0.		
Donadini MP., 2016	Patients were treated with LMWH for 4–6 weeks, given at a full therapeutic dose		
Donadiii Wii ., 2010	for 1 week followed by 50% of that dose for 3–5 weeks.		
Elmi G., 2023	Prophylactic dose: enoxaparin 4000 IU OD; LMWH administration could be		
Eiiii G., 2023	increased up to an intermediate dose (usually enoxaparin 6000 IU OD or 4000 IU		
	BID).		
Ferrara F., 2006	Therapeutic dose: nadroparin at 200 IU/kg/day, given in 2 doses.		
Horner D., 2014	Therapeutic dose: initial therapeutic dose of dalteparin with phased transition to		
	VKA for a total of 3 months. The target INR was 2.5 (range, 2.0-3.0).		
Huang Z.,2023	Prophylactic dose: 0.4 ml enoxaparin OD, followed by rivaroxaban 10 mg OD.		
	Therapeutic dose: 0.6 ml enoxaparin OD, followed by rivaroxaban 15 mg OD.		
Lagerstedt CI., 1985	Therapeutic dose: 5-day course of UFH intravenously, 500-600 IU/kg/day in 6		
	divided doses, followed by warfarin with an INR of 2.5-4.2.		
Merriman E., 2021	Therapeutic dose: full dose enoxaparin (1 mg/kg BID or 1.5 mg/kg OD) or		
	rivaroxaban (15 mg BID) for two weeks.		
Mo M., 2023	Full dose rivaroxaban 30 mg daily vs low dose rivaroxaban 15 mg daily at least for		
	3 months.		
Pellegrini VD., 1993	Warfarin prophylaxis was administered to patients as a two-step regimen,		
	beginning 7-14 days before surgery, to achieve an INR of 1.3-1.7 at the time of		

	surgery. After surgery, INR of 1.7-2.5 for the duration of the hospitalization, which averaged 11 days.
Pinede L., 2001	Therapeutic dose: VKAs to an INR of 2.0 to 3.0.
Righini M., 2016	Therapeutic dose: nadroparin 171 IU/kg/day.
Sartori M., 2024	Patients were randomized to LMWH 1 mg/kg BID for 2 weeks followed by 1
	mg/kg OD for 4 weeks or to enoxaparin 1 mg/kg BID and concurrent warfarin
	with a target INR of 2.5 for 3 months.
Schwarz T., 2010	Therapeutic dose: nadroparin 180 IU/kg OD.
Sule AA., 2009	Therapeutic dose: enoxaparin 1 mg/kg BID for 2 weeks or warfarin for 3 months
	with initial overlap of enoxaparin 1 mg/kg BID for 3 to 5 days until the INR was
	between 2.0 and 3.0.
Yamashita Y., 2023	Therapeutic dose: edoxaban 60 mg OD, or 30 mg OD in patients with a creatinine
	clearance of 30 to 50 mL per minute or a body weight of 60 kg or less or in those
	receiving concomitant treatment with potent P-glycoprotein inhibitors.

Abbreviations: APTT, activated partial thromboplastin time; BID, twice daily; DOACs, direct oral anticoagulants; INR, international normalized ratio; IU, international unit; LMWHs, low molecular weight heparins; OD, once daily; UFH, unfractionated heparin; VKAs, vitamin K antagonists.